Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers

Human Gene Therapy

Volumn 26, Issue 6, 2015, Pages 334-346

  Yan, Ziying ^a   Sun, Xingshen ^a   Feng, Zehua ^a   Li, Guiying ^a   Fisher, John T ^a   Stewart, Zoe A ^a   Engelhardt, John F ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PARVOVIRUS VECTOR; FIREFLY LUCIFERASE;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENHANCER REGION; FERRET; GENE DELETION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOME SIZE; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; TATA BOX; TG83 PROMOTER; TRANSCRIPTION INITIATION SITE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS RECOMBINANT; ANIMAL; CELL LINE; DEPENDOPARVOVIRUS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; LUNG; PROMOTER REGION; VIROLOGY;

ADENO-ASSOCIATED VIRUS; MUSTELA;

ANIMALS; CELL LINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDOVIRUS; ENHANCER ELEMENTS, GENETIC; EPITHELIAL CELLS; FERRETS; GENE EXPRESSION REGULATION; GENETIC VECTORS; GENOME, VIRAL; HUMANS; LUCIFERASES, FIREFLY; LUNG; PROMOTER REGIONS, GENETIC; TRANSGENES;

EID: 84932629728     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.001     Document Type: Article

References (54)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891-1904.
2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073.
3. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065.
4. Welsh MJ. Abnormal regulation of ion channels in cystic fibrosis epithelia. FASEB J 1990;4:2718-2725.
5. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
6. Welsh MJ, Tsui LC, Boat TF, et al. Cystic fibrosis. In: The Metabolic and Molecular Basis of Inherited Disease. CR Scriver, AL Beaudet, WS Sly, D Valle, eds. (McGraw-Hill, New York). 1995; pp. 3799-3876.
7. Sumner-Jones SG, Gill DR, Hyde SC. Gene Therapy for Cystic Fibrosis Lung Disease. (Birkhäuser Basel, Basel, Switzerland). 2010.
8. Mueller C, Flotte TR. Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol 2008;35:164-178.
9. Griesenbach U, Alton EW. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009;61:128-139.
10. Griesenbach U, Inoue M, Hasegawa M, et al. Viral vectors for cystic fibrosis gene therapy: what does the future hold? Virus Adapt Treat 2010;2:159-171.
11. Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther 2005;16:541-650.
12. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006;14:316-327.
13. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008;21:583-593.
14. Flotte TR. Recombinant adeno-associated virus vectors for cystic fibrosis gene therapy. Curr Opin Mol Ther 2001;3:497-502.
15. Aitken ML, Moss RB, Waltz DA, et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001;12:1907-1916.
16. Wagner JA, Nepomuceno IB, Messner AH, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002;13:1349-1359.
17. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2b trial. Hum Gene Ther 2007;18:726-732.
18. Duan D, Yue Y, Yan Z, et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000;105:1573-1587.
19. Duan D, Yue Y, Yan Z, et al. Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum Gene Ther 1998;9:2761-2776.
20. Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996;3:658-668.
21. Liu X, Luo M, Trygg C, et al. Biological differences in rAAV transduction of airway epithelia in humans and in Old World non-human primates. Mol Ther 2007;15:2114-2123.
22. Ding W, Zhang L, Yan Z, et al. Intracellular trafficking of adeno-associated viral vectors. Gene Ther 2005;12:873-880.
23. Yan Z, Zak R, Luxton GW, et al. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002;76:2043-2053.
24. Yan Z, Lei-Butters DC, Liu X, et al. Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia. J Biol Chem 2006;281:29684-29692.
25. Zhang LN, Karp P, Gerard CJ, et al. Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway. Mol Ther 2004;10:990-1002.
26. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996;7:2101-2112.
27. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther 2010;18:80-86.
28. Flotte TR, Afione SA, Solow R, et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993;268:3781-3790.
29. Aitken ML, Greene KE, Tonelli MR, et al. Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis. Chest 2003;123:792-799.
30. Zhang L, Wang D, Fischer H, et al. Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened cftr genes. Proc Natl Acad Sci U S A 1998;95:10158-10163.
31. Ostedgaard LS, Zabner J, Vermeer DW, et al. CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivo. Proc Natl Acad Sci U S A 2002;99:3093-3098.
32. -/- mice. Proc Natl Acad Sci U S A 2011;108:2921-2926.
33. Ostedgaard LS, Rokhlina T, Karp PH, et al. A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proc Natl Acad Sci U S A 2005;102:2952-2957.
34. Li W, Zhang L, Johnson JS, et al. Generation of novel aav variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther 2009;17:2067-2077.
35. Sun X, Yan Z, Yi Y, et al. Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets. J Clin Invest 2008;118:1578-1583.
36. Sun X, Sui H, Fisher JT, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest 2010;120:3149-3160.
37. Olivier AK, Yi Y, Sun X, et al. Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J Clin Invest 2012;122:3755-3768.
38. Sun X, Olivier AK, Liang B, et al. Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets. Am J Respir Cell Mol Biol 2014;50:502-512.
39. Sun X, Olivier AK, Yi Y, et al. Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets. Am J Pathol 2014;184:1309-1322.
40. Yan Z, Sun X, Evans IA, et al. Postentry processing of recombinant adeno-associated virus type 1 and transduction of the ferret lung are altered by a factor in airway secretions. Hum Gene Ther 2013;24:786-796.
41. Schlabach MR, Hu JK, Li M, et al. Synthetic design of strong promoters. Proc Natl Acad Sci U S A 2010:107:2538-2543.
42. Yan Z, Zak R, Zhang Y, et al. Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol 2004;78:2863-2874.
43. Ding W, Zhang LN, Yeaman C, et al. rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion. Mol Ther 2006;13:671-682.
44. Liu X, Luo M, Guo C, et al. Comparative biology of rAAV transduction in ferret, pig and human airway epithelia. Gene Ther 2007;14:1543-1548.
45. Karp PH, Moninger TO, Weber SP, et al. An in vitro model of differentiated human airway epithelia: methods for establishing primary cultures. Methods Mol Biol 2002;188:115-137.
46. Zabner J, Karp P, Seiler M, et al. Development of cystic fibrosis and noncystic fibrosis airway cell lines. Am J Physiol Lung Cell Mol Physiol 2003;284:L844-L854.
47. Yan Z, Keiser NW, Song Y, et al. A novel chimeric adenoassociated virus 2/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia. Mol Ther 2013;21:2181-2194.
48. Liu X, Luo M, Zhang L, et al. Bioelectric properties of chloride channels in human, pig, ferret, and mouse airway epithelia. Am J Respir Cell Mol Biol 2007;36:313-323.
49. Gerard CJ, Dell'aringa J, Hale KA, et al. A sensitive, realtime, RNA-specific PCR method for the detection of recombinant AAV-CFTR vector expression. Gene Ther 2003; 10:1744-1753.
50. Kapranov P, Chen L, Dederich D, et al. Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther 2012;23:46-55.
51. Glozman R, Okiyoneda T, Mulvihill CM, et al. N-Glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. J Cell Biol 2009;184:847-862.
52. Fisher JT, Liu X, Yan Z, et al. Comparative processing and function of human and ferret cystic fibrosis transmembrane conductance regulator. J Biol Chem 2012;287:21673-21685.
53. Fisher JT, Zhang Y, Engelhardt JF. Comparative biology of cystic fibrosis animal models. Methods Mol Biol 2011;742:311-334.
54. - transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 2005;289:L1123-L1130.